Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapy
Despite initial impaired antibody responses to SARS-CoV-2 vaccinations, patients with solid malignancies receiving chemotherapy effectively generated long-term cellular and humoral responses by 6 and 12 months, leading to similar infection and hospitalization rates compared to healthy individuals.
Authors
- Pooja Prem Advani (ORCID: https://orcid.org/0009-0007-5470-3149)
- A E Bharucha
- Gina Reynolds
- Ashita Mummareddy (ORCID: https://orcid.org/0000-0002-7176-5786)
- Davitte Cogen (ORCID: https://orcid.org/0000-0001-5846-7066)
- KL Knutson
- Christopher P. Marquez (ORCID: https://orcid.org/0000-0003-4244-3259)
- Melanie D. Swift (ORCID: https://orcid.org/0000-0002-5900-5573)
- Saranya Chumsri
- Mikolaj A. Wieczorek (ORCID: https://orcid.org/0000-0002-7879-9727)
- Andrew liu
- Alvaro Moreno-Aspitia
- Marites Acampora
- M. Necela Brian
- Tushar C. Patel
- Abinash Virk
- Zhuo Li
Institutions
- WinnMed (US)
- Cancer Clinic (US)
- Mayo Clinic Health System (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1690495
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00